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ABSTRACT Coexpression in Xenopus oocytes of the in-
wardly rectifying guanine nucleotide binding (G)-protein-
gated K channel GIRK1 with a myristoylated modification of
the (putative) cytosolic C-terminal tail [GIRK1 aa 183-501
fused in-frame to aa 1-15 of p6Osrc and denoted src+(183-
501)] leads to a high degree of inhibition of the inward
G-protein-gated K+ current. The nonmyristoylated segment,
src-(183-501), is not active. Although some interference with
assembly is not precluded, the evidence indicates that the main
mechanism of inhibition is interference with functional acti-
vation of the channel by G proteins. In part, the tail functions
as a blocking particle similar to a "Shaker ball"; it may also
function by competing for the available supply of free Gj8'y
liberated by hormone activation of a seven-helix receptor. The
non-G-protein-gated weak inward rectifier ROMK1 is less
effectively inhibited, and a Shaker K channel was not inhib-
ited. Immunological assays show the presence of a high
concentration of src+(183-501) in the plasma membrane and
the absence of any membrane forms for the nonmyristoylated
segment.
The inwardly rectifying guanine nucleotide binding (G)-protein-
gated atrial K channel [initially denoted GIRK1 (1) or KGA
(2); we used GIRK1 herein] was the first member of the
expanding GIRK subfamily of inwardly rectifying K (Kir)
channels to be cloned (for review, see ref. 3). Of all known Kir
channels, GIRKi has the longest C-terminal cytosolic tail (see,
for example, figure 1 of ref. 2), spanning aa 183-501. Regions
of significant sequence homology with non-G-protein-
activated inward rectifiers, such as ROMK1 and IRK1, end
around aa 360. There is also considerable sequence homology
within the region of aa 183-360 with two additional members
of the G-protein-gated inward rectifier family, mbGIRK2 and
mbGIRK3, which are expressed in mouse brain (4).
The relatively large length of the GIRK1 C-terminal seg-
ment and the presence of regions of homology and nonho-
mology with other members of the Kir family suggest that this
segment may play one or several roles in channel function,
including interactions with G proteins and with the conducting
pore. Furthermore, several recent studies of other IRKs have
indicated interactions between the C terminus and the respec-
tive channel pores (5, 6). The experiments described herein are
an initial study of the possible roles in gating of the segment
of aa 183-501. Specifically, we have coexpressed this segment
in oocytes as a free cytosolic segment or with an N-terminal
myristoylation signal, providing peripheral membrane attach-
ment. We find that overexpression of the membrane-attached
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form relative to GIRK1 leads to a marked decrease in hor-
mone-evoked GIRK1 currents. In effect, the myristoylated
segment of aa 183-501 can act as a dominant negative trun-
cation mutant. Our results are consistent with the hypothesis
that the segment of aa 183-501 functions as a blocking particle,
analogous, for example, to the N-terminal peptide of certain
rapidly inactivating Shaker-type K channels (7); and, in addi-
tion, it may inhibit gating of the channel by competitive binding
of activated G-protein subunits (probably GO3y; see Discus-
sion). A preliminary note describing this work has appeared
(8).
MATERIALS AND METHODS
Transcription Templates. GIRK1 complementary RNA
(cRNA) was prepared by in vitro transcription of the Xho
I-linearized pBluescript plasmid as described (2). The cRNA
for the segment of aa 183-501 [denoted src-(183-501)] was
generated from a cDNA derived by a two-step PCR procedure,
using primers that added to the 5' end a T7 promoter sequence
and a segment of the 5' untranslated region of alfalfa mosaic
virus plus a Kozak box and a poly(dA) tail to the 3' end of aa
183-501 (9, 10). For the myristoylation signal, the forward
PCR primer also provided the first 15 aa of p6osrc (11) fused
in-frame to aa 183 [denoted src+(183-501)].
Oocytes and Electrophysiology. These standard procedures
as practiced in our laboratories have been described (2).
Injected oocytes were incubated 3-8 days in ND96 solution (96
mM NaCl/2 mM KCl/1 mM CaCl2/1 mM MgCl2/5 mM
Hepes, pH 7.5/2.5 mM sodium pyruvate/gentamycin at 50
,g/ml). For most of the electrophysiology experiments, oo-
cytes clamped at -80 mV were perfused with ND96 without
pyruvate and antibiotics, which was then changed to hK
solution (96 mM KCl/1 mM NaCl/1 mM CaCl2/1 mM
MgCl2/5 mM Hepes, pH 7.5). Current/voltage curves were
recorded by voltage ramps lasting 1 sec.
Immunological Methods. The peptide KTRMEGNLPAK-
LRKMNSD, corresponding to aa 482-498 of GIRK1 with an
added N-terminal lysine, was synthesized, purified, and char-
acterized by the Caltech Microchemical Facility. The peptide
was coupled to bovine serum albumin and several antisera
raised in rabbits. Affinity-purified antibody was then prepared
by chromatography to the peptide coupled to CNBr-activated
Sepharose 4B.
For immunological localization, 20-,um sections were cut
from injected and uninjected oocytes that had been fixed in 2%
Abbreviations: cRNA, complementary RNA; m2AChR, m2 musca-
rinic acetylcholine receptor; IhK, high K current; IACh, acetylcholine-
induced current; G protein, guanine nucleotide binding protein.
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(wt/vol) paraformaldehyde and frozen in OCT embedding
compound. After incubation with antibody, sites of binding
were amplified by using the biotin amplification procedure,
visualized with lissamine rhodamine-conjugated streptavidin,
and photographed by using confocal microscopy (12).
Location and relative amounts of antigen were also mea-
sured by immunoprecipitation/gel electrophoretic methods.
As a control for the properties of the antibody with known
sources of antigen, reaction of the antibody with SDS-
solubilized membranes from rat atria, ventricle, and brain were
observed by Western blot analysis. Experiments on oocytes
were then carried out as described (13). Briefly, injected
oocytes were labeled with [35S]methionine from days 1 to 4
after cRNA injection. Plasma membranes were manually
separated from the remainder of the oocyte, which is referred
to as the "internal" fraction. The plasma membrane and
internal fractions were solubilized; antigen was immunopre-
cipitated and analyzed by gel electrophoresis and autoradiog-
raphy. In a second set of experiments, a total membrane pellet
was separated from the internal fractions; the soluble and
membrane bound fractions were subjected to gel analysis.
RESULTS
Suppression of GIRK1 Currents by src+(183-501). In our
standard paradigm for studying the electrophysiological
response of GIRK1, control oocytes were coinjected with
cRNAs encoding GIRK1 and a seven-helix receptor [for exam-
ple, the m2 muscarinic acetylcholine receptor (m2AChR)]; a
parallel group of oocytes (from the same batch) were injected
with these cRNAs and one encoding src+(183-501) or
src-(183-501). Similarly, the effects of src+(183-501) on
ROMK1 and Shaker (A6-46, inactivation removed) (7) were
also examined.
With control oocytes clamped at -80 mV, the bath medium
was shifted from ND96 to a high potassium (hK) medium, with
its major constituent being 96 mM KCl. The current induced
by this shift, denoted IhK, was due in part to the injected
exogenous GIRK1 and in part to a small but variable oocyte
K+ current. With GIRK1 and m2AChR but no src+(183-501)
cRNAs injected, addition of agonist (5 ,uM acetylcholine)
induced the relatively large inward K current of principal
interest here, IACh. For the present experiments IACh varied
from 100 nA to 1 ,uA, depending on the amount and batch
of the injected cRNA, oocyte batch, and time of incubation
(Fig. 1A).
When the non-G-protein-gated inward rectifier ROMK1
was used, the m2AChR was omitted. In this case IhK was large
(0.4-1.5 ,tA) and mainly due to ROMK1. The net IhK is
calculated as the change from ND96 to hK medium (Fig. 1B).
Compared to most other IRs, ROMK1 is weakly rectifying, i.e.,
more permeable for outward K currents (data not shown; see
ref. 14).
Our principal results are presented as the averaged data
from many experiments on different oocyte batches in Fig. iC.
A typical example of the reduced signal due to src+(183-501)
is shown in Fig. LA. In summary, coinjection of src+(183-501)
cRNA in excess over the amount of GIRK1 cRNA (and with
m2AChR present) resulted in a decrease of IACh to 27 + 2.7%
(mean + SEM) of that observed in controls with GIRK1 and
m2AChR. However, coinjection of 5 ng of cRNA for the
presumed cytosolic product src-(183-501) did not reduce the
level of IACh (96.6 + 17.5%). The inhibition of GIRK1 current
caused by src+(183-501) could be largely overcome by increas-
ing the amount of GIRK1 cRNA to 5 ng (Fig. 1C). Additional
experiments confirmed that at least 0.5 ng of src+(183-501)
cRNA and an excess over the amount of GIRK1 cRNA was
needed for significant inhibition (data not shown).
The question of whether src+(183-501) affects currentsfrom other K channels was addressed by studying its effect
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FIG. 1. Typical currents for injection into oocytes of cRNAs. (A)
Solid line, GIRK1 (40 pg) and m2AChR (200 pg); dotted line, GIRK1
(40 pg), m2AChR (200 pg), and src+(183-501) (2 ng) (this tracing has
been displaced slightly to the right for clarity). (B) ROMK1 (50 pg).
For this case, a tracing in the presence of src+(183-501) with a typical
40% inhibition is not shown. (C) Averaged data (numbers of oocytes
indicated over the bars; usually four or five tracings per oocyte) of the
effects of coinjection of src+(183-501) or of src-(183-501) on the
various channels. For GIRK1, m2AChR was always coinjected. For
each channel, the control (100% value) was based on experiments in
the same batch and with a comparable number of oocytes injected with
the channel but with neither src+(183-501) nor src-(183-501). In C
and Fig. 3, the abbreviations are as follows: Gl, GIRK1; src+,
src+(183-501); src-, src-(183-501); Sh, Shaker IR; R, ROMK1. [The
amount of Shaker IR RNA used actually varied between 75 and 200
pg, with an average of 130 pg (for further details, see text).]
on the voltage-gated Shaker channel and on the weak IR
ROMK1. Shaker currents were not significantly changed by
coexpressed src+(183-501) (91 ± 11% of control). However,
src+(183-501) cRNA did significantly reduce the level of
ROMK1 current to 59 + 5% of control.
The effect of the ratio of src+(183-501) to GIRK1 cRNAs
was studied in a separate set of experiments. With the amount
of GIRK1 cRNA fixed at 0.5 ng, a 1:1 ratio of src+(183-501)/
GIRK1 had no effect; 5:1 and 10:1 ratios caused 33% and 94%
inhibition, respectively.
These experiments indicate that inhibition by src+(183-501)
depends on having a sufficiently high ratio of src+(183-501) to
GIRK1 products in the plasma membrane, as expected for
inhibition by overexpression for any dominant negative mu-
tant; since the translation efficiencies to give functional protein
(i.e., in the plasma membrane) are unknown, a numerical ratio
cannot be stated. As shown in the immunohistochemical
experiments reported below, this ratio is in fact quite high.
One possible interpretation of inhibition of GIRK1 is that
the src+(183-501) segment interferes with assembly and/or
transport to the membrane of the presumed GIRK1 tetramer.
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That possibility was addressed in a sequential injection exper-
iment. As shown in Fig. 2, when GIRK1, m2AChR, and
src+(183-501) cRNAs were injected on day 0, there was
inhibition of IACh by "70% on day 4. When GIRK1 and
m2AChR were injected alone, the signal was increased only
slightly by day 8. However, the src+(183-501) inhibition was
quite small by day 8, suggesting that much of the src+(183-501)
mRNA and protein had decayed by this time. However, when
injection of src+(183-501) cRNA was delayed until 4 days after
the injection of GIRKi and m2AChR, there was inhibition by
"60% on day 8. We interpret this result to indicate that the
functional preexisting GIRK1 present on day 4 has been
inhibited by the src+(183-501) synthesized from days 4 to 8.
From these experiments, we conclude that inhibition is not
mainly due to interference with assembly of functional GIRKi
channels on the plasma membrane.
Immunochemical Localization of GIRK1, src+(183-501),
and src-(183-501). Fig. 3 exhibits results by one of the two
methods that has been used for immunological analyses of the
levels and locations of GIRK1, src+(183-501), and src-(183-
501) proteins within the oocyte. All experiments were per-
formed with an antiserum raised in rabbits to a peptide
corresponding to aa 482-498 of GIRK1.
Fig. 3C is a Western blot showing that a strong band of the
expected molecular mass of 56 kDa for GIRKi was observed
in atrial membranes with a weaker band for brain membranes
and none for ventricles. A cross-reacting band of unknown
identity at 40 kDa was observed in atria and ventricles. Fig. 3D
is an autoradiogram for an in vitro translation for GIRK1,
src+(183-501), and src-(183-501) cRNAs, showing that the
main protein bands have the expected molecular masses of
-55, 37, and 35 kDa. Thus, the results in Fig. 3 C and D
partially confirm the specificity of the antiserum and the
identity of the gene product encoded by the two cRNAs.
For Fig. 3 A and B, injected oocytes were labeled with
[35S]methionine. Plasma membranes were manually isolated;
the remainder of the oocyte is labeled internal and consists
principally of internal membranes and cytosol (13). Immuno-
precipitates from each fraction were analyzed by SDS/PAGE
and autoradiography. In the plasma membrane fraction (3B),
src+(183-501) gave two bands of molecular mass 44 and 42
kDa; as expected, no bands were detected for src-(183-501).
In the internal fraction (Fig. 3A), src+(183-501) showed the
same bands at 44 and 42 kDa and two bands at 39 and 37 kDa,
whereas src-(183-501) showed three bands at 40, 39, and 37
kDa. We surmise that the band heterogeneity is due to
unknown proteolytic or processing events and that the lower
molecular mass bands for src+(183-501) are nonmyristoylated
forms, similar or identical to the src-(183-501) bands.
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FIG. 2. Sequential injection experiment to test effect of later
injection of src+(183-501) on preexisting GIRK1channels (for further
details and discussion, see text). m2R, m2AChR.
For GIRK1 itself, it was necessary to inject 2.5-5 ng of
cRNA to obtain a strong signal from the 10-20 oocytes used
(Fig. 3A and B, lanes 5). For both the plasma membrane and
internal fractions, there was a doublet at the expected molec-
ular mass of -55 kDa and a fainter higher molecular mass
smear with a suggestion of discrete bands. Fig. 3A and B, lanes
4, shows extracts from oocytes injected with 40 pg of GIRK1
and 5 ng of src+(183-501); lanes 6 were for 40 pg of GIRK1
only. The GIRK1 signal was barely detectable, showing that
under the conditions used for the electrophysiological inhibi-
tion experiments, the ratio of src+(183-501) to GIRK1 was
high in both plasma membrane and internal fractions.
A second set of gel electrophoretic analyses of 35S-labeled
proteins from oocytes were carried out to estimate the relative
amounts of the several antigens in the internal fraction that
were in internal membrane and soluble fractions. After phys-
ical removal of the plasma membrane, the internal fraction was
divided into a crude membrane pellet and the cytosol fraction
(Fig. 3F). Immunoprecipitated antigens were analyzed. The
results (Fig. 3E and F) show that little or no src-(183-501) was
in the membrane pellet. For src+(183-501), the lower molec-
ular mass bands, which we suggest above are nonmyristoylated,
were primarily in the cytosol fraction. The 44- and 42-kDa
myristoylated isoforms were present in significant amounts in
both the membrane fraction and the cytosol. This result
indicates that, at least for a highly expressed molecule, my-
ristoylation is not sufficient to cause 100% membrane attach-
ment.
In an alternative immunohistochemical approach to subcel-
lular localization of expression, 20-,um slices were made from
fixed and frozen oocytes and stained with antibody. Fig. 4A
shows the weak background staining in uninjected oocytes.
Oocytes injected with 5 ng of GIRK1, src+(183-501), or
src-(183-501) are shown in Fig. 4 B, D, and C, respectively.
There was a high concentration of antigen in the plasma
membrane for src+(183-501) and a clear but lower concen-
tration for GIRK1. In each case, there was considerable
expression of antigen internally in the oocyte. For src-(183-
501), there was no antigen in the plasma membrane but diffuse
expression internally.
DISCUSSION
Our principal result is that overexpression of the myristoylated
membrane-attached form of the GIRK1 segment of aa 183-
501, which is the putative cytosolic tail, relative to the amount
of GIRK1 protein in the plasma membrane, causes inhibition
of the G-protein-gated signal (IACh in the present instance
using the m2AChR as the G-protein-coupled receptor) of the
full-length channel. Thus the membrane bound (aa 183-501)
segment functions as a dominant negative truncation mutant.
Many patch-clamp experiments have shown that G-protein
gating of the natural GIRK1 channel is a membrane-delimited
process; it is now generally accepted that Goy heterodimers
can bind to an internally exposed epitope(s) of GIRK1 and
induce channel opening. Experiments by J.G. (unpublished
data) and by C. Dessauer (University of Texas Southwestern
Medical Center, Dallas) (personal communication) indicate
(15, 16) that the segment of aa 183-501 when expressed by in
vitro translation in a rabbit reticulocyte system or as a gluta-
thionine S-transferase fusion in Escherichia coli can bind to
bovine Gply2.
The fact that the segment of aa 183-501 can suppress
ROMK1 currents suggests that this segment functions in part
as a blocking particle, similar to a "Shaker ball" for rapidly
inactivating voltage-gated K channels (7). The blocking effect
hypothesis is consistent with our observation (17) that the
peptide corresponding to aa 485-501 of GIRKi blocks the
channel in inside-out patches. We think it plausible, in view of
the direct biochemical evidence for binding, that suppression
T
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FIG. 3. Immunochemical/gel electrophoretic analyses of expression of GIRK1, src+(183-501), and src-(183-501) in membranes and cytosol
fractions of injected oocytes. (C) Western blot of membranes (50 ,±g of protein per lane) from rat heart ventricles (V) and atria (A) and rat brain
(B) reacted with the GIRK1 antiserum. (D) In vitro translation in a rabbit reticulocyte system of the cRNAs for GIRK1, src+(183-501), and
src-(183-501). Lanes: 1 and 6, 14C and the rainbow molecular weight markers (Amersham); 2, src-(183-501); 3, GIRK1; 4, src+(183-501) (for lanes
2-4, the principal band is identified by an arrow); 5, control translation with no added cRNA. The gel electrophoretic pattern for GIRK1 was
essentially the same in the presence of dog pancreas microsomal membranes; in this case, however, most of the translated protein could be pelleted
with the membranes (data not shown). (A, B, E, and F) Injected oocytes were metabolically labeled with [35S]methionine. The several fractions
were prepared by using 10-20 oocytes, each injected with 5 ng of GIRK1 and/or 2.5-5 ng of src+(183-501) or src-(183-501); except that inA and
B, lanes 4 and 6, 40 pg of GIRK1 was used. Extracted fractions were immunoprecipitated, gel-separated, and analyzed by autoradiography. (A)
Manually dissected plasma membranes (PM). (B) The remainder of the oocytes, i.e., cytosol plus intemal organelles labeled internal. (E and F)
Plasma membranes were manually removed; the remaining internal fraction was divided into a soluble (true cytosol) fraction (F), labeled solution,
and a membrane pellet fraction (E), labeled internal membrane. For all these experiments, antiserum rather than affinity-purified antibody was
used. Gl, GIRK1; src- and src+, src-(183-501) and src+(183-501), respectively.
by the segment of aa 183-501 also involves competitive binding
of hormone-liberated Gfryby the segment of aa 183-501 under
conditions when the latter is relatively abundant at the mem-
brane compared to GIRK1. [Coexpression of Gfl and G-y2 in
oocytes with GIRK1 converts a major fraction of IACh to IhK
(16, 18)]. However, our attempts to demonstrate competition
by overriding src+(183-501) suppression by G,B plus Gy ex-
pression were not successful (data not shown). We regard this
experiment as inconclusive because of lack of knowledge of the
amount of free Gfy in the oocyte under the conditions used.
Thus, although we believe it to be likely that the inhibition
phenomenon is in part due to competitive binding of GI3y,
there is no direct experimental evidence to support the hy-
pothesis.
Both the gel electrophoretic (Fig. 3) and the immunohisto-
chemical (Fig. 4) experiments indicate that under the condi-
tions where src+(183-501) inhibits GIRK1 currents [i.e., 2.5-5
ng of src+(183-501) cRNA and 0.5 ng or less (usually 0.04 ng)
of GIRK1], there is a high ratio of src+(183-501) protein to
GIRK1 protein in the functionally important plasma mem-
brane. This is consistent with the general interpretation of
dominant negative inhibition.
In several instances, truncated subunits of an oligomeric
channel may coassemble with intact subunits to give nonfunc-
tional heterooligomers and thus function as dominant negative
mutants. This has been reported for short N-terminal domains
of the mammalian delayed rectifier Kv1.1 channel, which
include the Si transmembrane segment (19). Similarly, expres-
sion of fragments of the a, 8, or y subunits of the mouse muscle
acetylcholine receptor consisting solely of the extracellular
N-terminal domain was sufficient to form complexes with
intact subunits and thus function as dominant negative mu-
tants (20). Furthermore, it has been shown that the hydrophilic
N-terminal domain of a Shaker voltage-gated K channel can
3 4 5 6 C V B A
200-
D
F solution
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coassemble with intact subunits to give nonfunctional channels
(21).
The question of whether the myristoylated segment of aa
183-501 functions in this manner was addressed in the delayed
injection experiment of Fig. 2. When GIRK1 cRNA was
injected on day 0, there was -530 nA of IACh expressed by day
4. On average, this was unchanged by day 6 or 8. However,
when src+(183-501) was injected on day 4, the current was
greatly inhibited (70%) by day 6 or 8. While an alternative
interpretation of this experiment based on rapid protein
turnover and resynthesis is conceivable, the straightforward
interpretation is that src+(183-501) synthesized over the 2- to
4-day period from day 4 to 8 acted as a dominant negative
functional inhibitor of preexisting GIRK1.
The observed partial inhibition of ROMK1 current suggests
that the membrane-attached myristoylated segment of aa
183-501 can also function as a blocking particle for an inward
rectifier K channel. The inhibition of ROMK1 currents is not
voltage-dependent, thus indicating no major electrostatic con-
tribution to the blocking action of the segment of aa 183-501
(data not shown); this is unlike the case for Shaker balls (7).
Biochemical experiments using two assays have indicated
that the segment of aa 183-501 expressed as an in vitro
translation product in a rabbit reticulocyte system (J.G.,
unpublished data) or as a glutathione S-transferase fusion in
E. coli (C. Dessauer, personal communication) can bind to
Gf3ly2. Since most Gf3y subunits in mammalian cells have
peripheral membrane attachment signals, we think it likely that
the membrane-attached segment of aa 183-501 can bind free
3,y subunits released by activation of a seven-helix receptor and
thus function to interfere with activation of GIRK1, or other
enzymes for which Gf3y is an effector, in oocytes and other
mammalian cells.
The system described here may provide an additional tool
for exploring the sequence requirements in the domain of aa
183-501 for interference with GIRK1 activation.
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